Dr Lorenz von Seidlein from our MORU unit in Bangkok, Thailand, tells us about his research on malaria elimination in the Greater Mekong sub-region
Malaria elimination in the Greater Mekong sub-region
Loading Video...
Multidrug resistant P. falciparum malaria is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for artemisinin combination therapies, the main falciparum malaria medicines.
A further spread from Myanmar to India then sub-Saharan Africa would be a global public health disaster. TME seeks the best ways to eliminate drug-resistant malaria, using both technical solutions and novel ways that engage entire communities.
Dr Lorenz von Seidlein coordinates MORU’s Targeted Malaria Elimination (TME) study, which seeks to eliminate artemisinin resistant falciparum malaria by treating entire communities that have significant levels of subclinical malaria parasite infections and transmission with the antimalarial Dihydroartemisinin-piperaquine (DHA-PIP).
Series:
People:
Oxford Unit:
More in this Series...
Malaria is an endemic disease in much of the world, and is a major contributor to child and infant mortality in many countries. Our malaria podcasts describe efforts by NDM clinicians and scientists, in Oxford and around the world, to treat and prevent malaria, including vaccine development, parasitology, and improved treatment for severe malaria, with the aim to lessen the disease burden on some of the world's most vulnerable people.
Subscribe
Download Media
- Video (489.1 MB)